Shaked
Abraham Shaked, Wynnewood, PA US
Patent application number | Description | Published |
---|---|---|
20130012860 | METHODS AND COMPOSITIONS TO PREDICT AND DETECT ACUTE REJECTION - In some embodiments, a method to detect acute rejection in allograft from is described. In some embodiments, a method to anticipate an episode of acute rejection in allografts is also described. In some embodiments, a kit for detecting or predicting acute transplant rejection of a transplanted organ is described. | 01-10-2013 |
20140213533 | METHODS TO DETECT, TREAT AND PREVENT ACUTE CELLULAR REJECTION IN KIDNEY ALLOGRAFTS - Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3ε mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts. | 07-31-2014 |
Amir Shaked, North Bergen, NJ US
Patent application number | Description | Published |
---|---|---|
20140071224 | SYSTEM AND METHOD FOR AGENT-BASED INTEGRATION OF INSTANT MESSAGING AND VIDEO COMMUNICATION SYSTEMS - A method and related apparatus for initiating videoconferences in instant messaging systems is described, including using an agent to represent the videoconferencing system into the instant messaging system and enabling control using hyperlinked information posted by the agent into the instant messaging message area. | 03-13-2014 |
Doron Shaked, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20080267524 | AUTOMATIC IMAGE ENHANCEMENT - This invention provides a method for automated image enhancement. Attribute measurements are extracted from a digital image and used for the generation of at least a noise threshold parameter, a sharpness parameter and a radicality parameter. The noise threshold parameter and sharpness parameter are evaluated to determine the degree of noise reduction and the degree of sharpening to be performed, collectively a determined enhancement. The determined enhancement is applied to derive a nominally enhanced image. With respect to the radicality parameter, the output image is the weighted average between the initial image and the nominally enhanced image. | 10-30-2008 |
Elad Shaked, Carlsbad, CA US
Patent application number | Description | Published |
---|---|---|
20150333947 | PEAK TO AVERAGE POWER RATIO SUPPRESSION - A transmitter comprises a first peak-to-average-power ratio (PAPR) suppression circuit, a second peak-to-average-power ratio (PAPR) suppression circuit, and a first modulator. The first PAPR suppression circuit may receive a first sequence of time-domain symbols to be transmitted, alter the first sequence based on each of a plurality of symbol ordering and/or inversion descriptors to generate a corresponding plurality of second sequences of time-domain symbols, measure a PAPR corresponding to each of the second sequences, select one of the plurality of symbol ordering and/or inversion descriptors based on the measurement of PAPR, and convey the selected one of the symbol ordering and/or inversion descriptors to the second PAPR suppression circuit. The second PAPR suppression circuit may receive the first sequence of time-domain symbols to be transmitted, and alter the first sequence based on the selected one of the symbol ordering and/or inversion descriptors to generate a reordered and/or inverted symbol sequence. | 11-19-2015 |
Iftach Shaked, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20130095127 | METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) - The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptides, Gal-3BP compositions, and methods of use, and uses, for example, in treatment, diagnostic, detection and prognostic methods, such as treatment of an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation, and treatment of an autoimmune response, disorder or disease. | 04-18-2013 |
Iftach Shaked, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20130108602 | METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE | 05-02-2013 |
Motti Shaked, Vancouver CA
Patent application number | Description | Published |
---|---|---|
20100192055 | APPARATUS, METHOD AND ARTICLE TO INTERACT WITH SOURCE FILES IN NETWORKED ENVIRONMENT - A subject of a file's content which is stored on a physical storage medium at a logical address in a networked system may be determined and used to identify the file to facilitate retrieval and/or the provision of information about the file, for example via forums or messages. | 07-29-2010 |
Nir Shaked US
Patent application number | Description | Published |
---|---|---|
20150339670 | SYSTEM AND METHOD FOR AUTHENTICATING A TRANSACTION OVER A DATA NETWORK - A method for authenticating a transaction between an initiator device and a transactor device over a data network, according to which a transaction request is submitted to the transactor device over the data network and an initiator determined one time parameter (OTP) is generated, based on parameters that are associated with the transaction request and with initiator activity. The initiator determined OTP is compared with a non-initiator determined OTP, both generated by means of an identical OTP engine. The transaction is denied if the initiator determined OTP and the non-initiator determined OTP are found to be different. The initiator activity is interfacing with a puzzle that is randomly selected and displayed on the initiator device, where the OTP engine generates an OTP as a function of parameters of the transaction request and of a puzzle result associated with the puzzle transmitted to the initiator device. | 11-26-2015 |
Tal Shaked, Los Altos, CA US
Patent application number | Description | Published |
---|---|---|
20150186794 | TEMPLATE REGULARIZATION FOR GENERALIZATION OF LEARNING SYSTEMS - Systems and techniques are disclosed for training a machine learning model based on one or more regularization penalties associated with one or more features. A template having a lower regularization penalty may be given preference over a template having a higher regularization penalty. A regularization penalty may be determined based on domain knowledge. A restrictive regularization penalty may be assigned to a template based on determining that a template occurrence is below a stability threshold and may be modified if the template occurrence meets or exceeds the stability threshold. | 07-02-2015 |
20150186795 | Multistage Learner for Efficiently Boosting Large Datasets - Implementations of the disclosed subject matter provide methods and systems for using a multistage learner for efficiently boosting large datasets in a machine learning system. A method may include obtaining a first plurality of examples for a machine learning system and selecting a first point in time. Next, a second point in time occurring subsequent to the first point in time may be selected. The machine learning system may be trained using m of the first plurality of examples. Each of the m examples may include a feature initially occurring after the second point in time. In addition, the machine learning system may be trained using n of the first plurality of examples, and each of the n examples may include a feature initially occurring after the first point in time. | 07-02-2015 |
Yuval Shaked, Toronto CA
Patent application number | Description | Published |
---|---|---|
20080214509 | Methods for enhancing the efficacy of vascular disrupting agents - This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Antagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF-1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent. | 09-04-2008 |
20110110940 | Methods for Enhancing the Efficacy of Vascular Disrupting Agents - This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject an α4β1 integrin antagonist sequentially or simultaneously in combination with said Vascular Disrupting Agent. | 05-12-2011 |
Ze'Ev Shaked, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20080299204 | Dosage forms for movement disorder treatment - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual. | 12-04-2008 |
20090269403 | ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of drugs for use as a female oral contraceptive. In an embodiment, an oral dosage form includes a progestogen dispersed in an enteric polymer and an estrogen. | 10-29-2009 |
20100316712 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration. | 12-16-2010 |
20110236462 | INTRAVAGINAL DRUG DELIVERY DEVICE - Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female. | 09-29-2011 |
20110250274 | ESTRIOL FORMULATIONS - Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations. | 10-13-2011 |